Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase

Current Pharmaceutical Design

Volumn 12, Issue 35, 2006, Pages 4555-4564

  Lai, Luhua ^a,b   Han, Xiaofeng ^a,b   Chen, Hao ^a,b   Wei, Ping ^a   Huang, Changkang ^a   Liu, Shiyong ^a,b   Fan, Keqiang ^a   Zhou, Lu ^a   Liu, Zhenming ^a   Pei, Jianfeng ^a   Liu, Ying ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Enzyme catalytic mechanism; Inhibitor design; Quaternary structure; SARS 3C like proteinase; Substrate selectivity

Indexed keywords

C 3930; CHYMOTRYPSIN; CINANSERIN; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; FL 166; GLUTAMINE DERIVATIVE; HEXACHLOROPHENE; INTERFERON; ISATIN DERIVATIVE; MAC 13985; MAC 22272; MAC 30731; MAC 5576; MAC 8120; MP 576; OXINDOLE; PROTEINASE; PROTEINASE INHIBITOR; RIBAVIRIN; RUPINTRIVIR; VIRUS PROTEIN;

COMMON COLD; DISSOCIATION CONSTANT; DRUG DESIGN; DRUG DETERMINATION; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME STRUCTURE; EXPERIMENTAL MODEL; GEL FILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN RHINOVIRUS; IC 50; IN VITRO STUDY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN QUATERNARY STRUCTURE; QUANTITATIVE ANALYSIS; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; ULTRACENTRIFUGATION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CATALYTIC DOMAIN; COMPUTER-AIDED DESIGN; CYSTEINE ENDOPEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, CHEMICAL; PROTEASE INHIBITORS; PROTEIN STRUCTURE, QUATERNARY; SARS VIRUS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; VIRAL PROTEINS;

EID: 33751504087     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206779010396     Document Type: Review

References (64)

1. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348(20): 1986-1994.
2. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348(20): 1995-2005.
3. Holmes KV. SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 2003; 111(11): 1605-1609.
4. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, et al. The Genome sequence of the SARS-associated coronavirus. Science 2003; 300(5624): 1399-1404.
5. Ruan YJ, Wei CL, Ee AL, Vega VB, Thoreau H, Su ST, et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003; 361(9371): 1779-1785.
6. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CL(pro)) structure: Basis for design of anti-SARS drugs. Science 2003; 300(5626): 1763-1767.
7. Liu S, Pei J, Chen H, Zhu X, Liu Z, Ma W, et al. Modeling of the SARS coronavirus main proteinase and conformational flexibility of the active site. Beijing Da Xue Xue Bao 2003; 35 Suppl: 62-65.
8. Xiong B, Gui CS, Xu XY, Luo C, Chen J, Luo HB, et al. A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening. Acta Pharm Sinica 2003; 24(6): 497-504.
9. Anand K, Palm GJ, Mesters JR, Siddell SG, Ziebuhr J, Hilgenfeld R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J 2002; 21(13): 3213-3224.
10. Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci USA 2003; 100(23): 13190-13195.
11. Hsu MF, Kuo CJ, Fang JM, Shie JJ, Chang KT, Chang HC, et al. Understanding the maturation process and inhibitor design of SARS-CoV 3CLpro from the crystal structure of C145A in a product-bound form. J Biol Chem 2005; 280(35): 31257-31266.
12. Bergmann EM, Mosimann SC, Chernaia MM, Malcolm BA, James MN. The refined crystal structure of the 3C gene product from hepatitis A virus: specific proteinase activity and RNA recognition. J Virol 1997; 71(3): 2436-2448.
13. Matthews DA, Smith WW, Ferre RA, Condon B, Budahazi G, Sisson W, et al. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 1994; 77(5): 761-771.
14. Dragovich PS, Prins TJ, Zhou R, Brown EL, Maldonado FC, Fuhrman SA, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics. J Med Chem 2002; 45(8): 1607-1623.
15. Dragovich PS, Prins TJ, Zhou R, Johnson TO, Brown EL, Maldonado FC, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics. Bioorg Med Chem Lett 2002; 12(5): 733-738.
16. Dragovich PS, Zhou R, Webber SE, Prins TJ, Kwok AK, Okano K, et al. Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors. Bioorg Med Chem Lett 2000; 10(1): 45-48.
17. Johnson TO, Hua Y, Luu HT, Brown EL, Chan F, Chu SS, et al. Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease. J Med Chem 2002; 45(10): 2016-2023.
18. Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci USA 1999; 96(20): 11000-11007.
19. Fan KQ, Wei P, Feng Q, Chen SD, Huang CK, Ma L, et al. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J Biol Chem 2004; 279(3): 1637-1642.
20. Chou CY, Chang HC, Hsu WC, Lin TZ, Lin CH, Chang GG. Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease. Biochemistry 2004; 43(47): 14958-14970.
21. Laue TM, Stafford WF III. Modern applications of analytical ultracentrifugation. Annu Rev Biophys Biomol Struct 1999; 28: 75-100.
22. Lebowitz J, Lewis MS, Schuck P. Modern analytical ultracentrifugation in protein science: a tutorial review. Protein Sci 2002; 11(9): 2067-2079.
23. Wei P, Fan KQ, Chen H, Ma L, Huang CK, Tan L, et al. The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase. Biochem Biophys Res Comm 2006; 339(3): 865-872.
24. Kuo CJ, Chi YH, Hsu JT, Liang PH. Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate. Biochem Biophys Res Commun 2004; 318(4): 862-867.
25. Chen H, Wei P, Huang C, Tan L, Liu Y, Lai L. Only one protomer is active in the dimer of SARS 3C-like proteinase. J Biol Chem 2006; 281(20): 13894-13898.
26. Holzman TF, Kohlbrenner WE, Weigl D, Rittenhouse J, Kempf D, Erickson J. Inhibitor stabilization of human immunodeficiency virus type-2 proteinase dimer formation. J Biol Chem 1991; 266(29): 19217-19220.
27. Todd MJ, Semo N, Freire E. The Structural Stability of the HIV-1 Protease. J Mol Biol 1998; 283(2): 475-488.
28. Jiang L, Gao Y, Mao FL, Liu ZJ, Lai LH. Potential of mean force for protein-protein interaction studies. Proteins 2002; 46(2): 190-196.
29. Jones S, Thornton JM. Principles of protein-protein interactions. Proc Natl Acad Sci USA 1996; 93(1): 13-20.
30. Ding L, Zhang XX, Wei P, Fan KQ, Lai LH. The interaction between severe acute respiratory syndrome coronavirus 3C-like proteinase and a dimeric inhibitor by capillary electrophoresis. Anal Biochem 2005; 343(1): 159-165.
31. Asboth B, Stokum E, Khan IU, Polgar L. Mechanism of action of cysteine proteinases: oxyanion binding site is not essential in the hydrolysis of specific substrates. Biochemistry 1985; 24(3): 606-609.
32. Brocklehurst K, O'Driscoll M, Kowlessur D, Phillips IR, Templeton W, Thomas EW, et al. The interplay of electrostatic and binding interactions determining active centre chemistry and catalytic activity in actinidin and papain. Biochem J 1989; 257(1): 309-310.
33. Dardenne LE, Werneck AS, de Oliveira NM, Bisch PM. Electrostatic properties in the catalytic site of papain: a possible regulatory mechanism for the reactivity of the ion pair. Proteins 2003; 52(2): 236-253.
34. Johnson FA, Lewis SD, Shafer JA. Perturbations in the free energy and enthalpy of ionization of histidine-159 at the active site of papain as determined by fluorescence spectroscopy. Biochemistry 1981; 20(1): 52-58.
35. Sarkany Z, Szeltner Z, Polgar L. Thiolate-imidazolium ion pair is not an obligatory catalytic entity of cysteine peptidases: the active site of picornain 3C. Biochemistry 2001; 40(35): 10601-10606.
36. Sarkany Z, Polgar L. The unusual catalytic triad of poliovirus protease 3C. Biochemistry 2003; 42(2): 516-522.
37. Connolly KM, Smith BT, Pilpa R, Ilangovan U, Jung ME, Clubb RT. Sortase from Staphylococcus aureus Does Not Contain a Thiolate-Imidazolium Ion Pair in Its Active Site. J Biol Chem 2003; 278(36): 34061-34065.
38. Hegyi A, Friebe A, Gorbalenya AE, Ziebuhr J. Mutational analysis of the active centre of coronavirus 3C-like proteases. J Gen Virol 2002; 83(Pt 3): 581-593.
39. Huang CK, Wei P, Fan KQ, Liu Y, Lai LH. 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. Biochemistry 2004; 43(15): 4568-4574.
40. Shan YF, Li SF, Xu GJ. A novel auto-cleavage assay for studying mutational effects on the active site of severe acute respiratory syndrome coronavirus 3C-like protease. Biochem Biophys Res Comm 2004; 324(2): 579-583.
41. Shi JH, Wei Z, Song JX. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme - Defining the extra domain as a new target for design of highly specific protease inhibitors. J Biol Chem 2004; 279(23): 24765-24773.
42. Fan KQ, Ma L, Han XF, Liang HH, Wei P, Liu Y, et al. The substrate specificity of SARS coronavirus 3C-like proteinase. Biochem Biophys Res Comm 2005; 329(3): 934-940.
43. Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS: A new trick for an old drug? CMAJ 2003; 168(10): 1289-1292.
44. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet 2003; 362(9380): 293-294.
45. Skowronski DA, Astell C, Brunham RC, Low DE, Petric M, Roper RL, et al. Severe acute respiratory syndrome (SARS): A year in review. Ann Rev Med 2005; 56: 357-381.
46. Chou KC, Wei DQ, Zhong WZ. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Comm 2003; 308(1): 148-151.
47. Liu B, Zhou JJ. SARS-CoV protease inhibitors design using virtual screening method from natural products libraries. J Comp Chem 2005; 26(5): 484-490.
48. Liu ZM, Huang CK, Fan KQ, Wei P, Chen H, Liu SY, et al. Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase. J Chem Inf Mod 2005; 45(1): 10-17.
49. Kuang WF, Chow LP, Wu MH, Hwang LH. Mutational and inhibitive analysis of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer-based assays. Biochem Biophys Res Comm 2005; 331(4): 1554-1559.
50. Chen S, Chen LL, Luo HB, Sun T, Chen J, Ye F, et al. Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique. Acta Pharm Sinica 2005; 26(1): 99-106.
51. Blanchard JE, Elowe NH, Huitema C, Fortin PD, Cechetto JD, Eltis LD, et al. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem Biol 2004; 11(10): 1445-1453.
52. Parera M, Clotet B, Martinez MA. Genetic screen for monitoring severe acute respiratory syndrome coronavirus 3C-like protease. J Virol 2004; 78(24): 14057-14061.
53. Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, Cheng YS, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci USA 2004; 101(27): 10012-10017.
54. Chen L, Gui C, Luo X, Yang Q, Gunther S, Scandella E, et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol 2005; 79(11): 7095-7103.
55. Kao RY, Tsui WHW, Lee TSW, Tanner JA, Watt RM, Huang JD, et al. Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem Biol 2004; 11(9): 1293-1299.
56. Hsu JT, Kuo CJ, Hsieh HP, Wang YC, Huang KK, Lin CP, et al. Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. FEBS Lett 2004; 574(1-3): 116-120.
57. Jain RP, Pettersson HI, Zhang J, Aull KD, Fortin PD, Huitema C, et al. Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro. J Med Chem 2004; 47(25): 6113-6116.
58. Shie JJ, Fang JM, Kuo CJ, Kuo TH, Liang PH, Huang HJ, et al. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease. J Med Chem 2005; 48(13): 4469-4473.
59. Bacha U, Barrila J, Velazquez-Campoy A, Leavitt SA, Freire E. Identification of novel inhibitors of the SARS coronavirus main protease 3CL(pro). Biochemistry 2004; 43(17): 4906-4912.
60. Chen LR, Wang YC, Lin YW, Chou SY, Chen SF, Liu LT, et al. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors. Bioorg Med Chem Lett 2005; 15(12): 3058-3062.
61. Zhou L, Liu Y, Zhang WL, Wei P, Huang CK, Pei JF, et al. Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors. J Med Chem 2006; in press.
62. Evangelista S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des 2004; 10(28): 3561-8.
63. Gomtsyan A, Lee CH. Nonnucleoside inhibitors of adenosine kinase. Curr Pharm Des 2004; 10(10): 1093-103.
64. Sakoff JA, McCluskey A. Protein phosphatase inhibition: structure based design. Towards new therapeutic agents. Curr Pharm Des 2004; 10(10): 1139-59.